`
`Page 1 of 1
`
`Orange Book: Approved Drug
`Products with Therapeutic
`Equivalence Evaluations
`
`(cid:1) SHARE (HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?U=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/
`CDER/OB/RESULTS_PRODUCT.CFM?APPL_TYPE=N&APPL_NO=020597)
`
`(cid:2) TWEET (HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERA
`PEUTIC EQUIVALENCE EVALUATIONS&URL=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/RESULTS_PRO
`DUCT.CFM?APPL_TYPE=N&APPL_NO=020597)
`
`+ (cid:4)
`
`EMAIL (MAILTO:?SUBJECT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVA
`LUATIONS&BODY=HTTPS://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/RESULTS_PRODUCT.CFM?APPL_TYPE=N
`&APPL_NO=020597)
`
`Home (default.cfm?resetfields=1) | Back to Search Results
`
`Product Details for NDA 020597
`
`XALATAN (LATANOPROST)
`0.005%
`
`Marketing Status: Prescription
`
`Active Ingredient: LATANOPROST
`Proprietary Name: XALATAN
`Dosage Form; Route of Administration: SOLUTION/DROPS; OPHTHALMIC
`Strength: 0.005%
`Reference Listed Drug: Yes
`Reference Standard: Yes
`TE Code: AT
`Application Number: N020597
`Product Number: 001
`Approval Date: Jun 5, 1996
`Applicant Holder Full Name: PHARMACIA AND UPJOHN CO
`Marketing Status: Prescription
`Patent and Exclusivity Information (patent_info.cfm?Prod-
`uct_No=001&Appl_No=020597&Appl_type=N)
`
`https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=N&Appl...
`
`5/11/2017
`
`Micro Labs Exhibit 1016
`
`